Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 18 Oct 2004 |
| Genmab, notification from major shareholder (section 29) from Morgan Stanley & Co. International | 15 Oct 2004 |
| Genmab, Announces Positive Phase I/II HuMax-EGFr Safety Data | 4 Oct 2004 |
| InvestorService: Genmab, to present at UBS Global Life Sciences Conference | 23 Sept 2004 |
| Genmab, Dr. Ernst Schweizer extends his Contract as Genmab’s Head of Business Development | 22 Sept 2004 |